675 West Kendall Street, Mass Innovation Labs
33 articles about EdiGene
The Beijing-based biotech will use the Series B funds to further their hematopoietic disease and cancer therapies pipeline and expand team.
EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage
EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced the successful completion of a RMB 450 million Series B financing.
EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer
EdiGene, Inc. and Immunochina announced that they have formed a research and development collaboration to develop allogeneic CAR-T therapy for cancer.
EdiGene to Present Data on its Lead RNA Base Editing Program to Treat Patients with the Most Severe Form of MPS I
EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, will present data on its lead therapeutic program for patients with the most severe form of mucopolysaccharidosis type I (MPS I), known as Hurler syndrome, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on Tuesday, May 12, 2020
EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development of Its Leading Gene Editing Therapeutic Program to Treat Patients with β-Thalassemia Major
EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced presentation of preclinical data on ET-01, its leading therapeutic program for patients with β-Thalassemia Major, during the 61st American Society of Hematology (ASH) Annual Meeting taking place in Orlando, FL on December 7-10th, 2019.
Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer
EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of raising approximately $11 Million in a Series pre-B2 financing.
EdiGENE Changes Name to Modalis Therapeutics
EdiGENE Corporation announced that the company has changed its name to Modalis Therapeutics Corporation.
Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio
Largest off-the-shelf diploid KO library, over 2,800 cell lines
EdiGENE Raises $15 Million in Series B Funding
EdiGENE, an emerging biotechnology company developing new CRISPR based therapies for treatment of genetic disorders, announced that it has raised 1.6 Billion-yen as the first tranche of Series B round.
Genome Editing Biotech EdiGene Raises $10 Million in Series pre-B Plus Financing and Strengthens Management Team
The new round of financing is led by new investor Green Pine Capital Partners (Green Pine). Series A lead investor IDG Capital, Series B lead investor Lilly Asia Ventures (LAV) and other insiders also participated in this round.
Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing
EdiGene Inc.today announced the successful completion of approximately $15 Million in a Series pre-B financing.
Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief Executive Officer
EdiGene Inc., announced that it has named Dong Wei, Ph.D., MBA, an experienced biopharmaceutical executive, as its chief executive officer. Dr. Dong Wei brings extensive experiences in strategic planning and execution across various stages of biopharmaceutical development, from discovery to clinical development and registration.
FUJIFILM signed an agreement on December 19th for the investment of 470 million yen in EdiGene, a drug discovery startup, participating its series A round.